NEW YORK, Nov. 18, 2023 (GLOBE NEWSWIRE) — Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to:
Coffee Holding Co., Inc. (NASDAQ: JVA)’s merger with Delta Corp Holdings Limited. If you are a Coffee shareholder, click here to learn more about your rights and options.
Summit Financial Group, Inc. (NASDAQ: SMMF)’s sale to Burke & Herbert Financial Services Corp. for 0.5043 shares of Burke & Herbert common stock for each share of Summit common stock. If you are a Summit shareholder, click here to learn more about your rights and options.
RPT Realty (NYSE: RPT)’s sale to Kimco Realty for 0.6049 of a newly-issued Kimco share for each RPT share. At closing, RPT shareholders are expected to own approximately 8% of the combined company. If you are a RPT shareholder, click here to learn more about your rights and options.
Standard BioTools Inc. (NASDAQ: LAB)’s merger with SomaLogic, Inc. Under the terms of the agreement, SomaLogic shareholders will receive 1.11 shares of Standard BioTools common stock for each share of SomaLogic common stock owned. Upon closing of the proposed transaction, Standard BioTools shareholders will own approximately 43% of the combined company. If you are a Standard BioTools shareholder, click here to learn more about your rights and options.
Shareholders are encouraged to contact the firm free of charge to discuss their legal rights and options. Please call Daniel Sadeh or Zachary Halper at (212) 763-0060 or email firstname.lastname@example.org or email@example.com.
Halper Sadeh LLC represents investors all over the world who have fallen victim to securities fraud and corporate misconduct. Our attorneys have been instrumental in implementing corporate reforms and recovering millions of dollars on behalf of defrauded investors.
Attorney Advertising. Prior results do not guarantee a similar outcome.
Halper Sadeh LLC
Daniel Sadeh, Esq.
Zachary Halper, Esq.
- Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar - December 11, 2023
- Disc Presents Initial Positive Data from Ongoing Phase 1b/2 Trial of DISC-0974 in Patients with Myelofibrosis (MF) and Anemia at the 65th American Society of Hematology (ASH) Annual Meeting - December 11, 2023
- Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development - December 11, 2023